SpyGlass Pharma, Inc. (SGP) Stock Price & Analysis
SpyGlass Pharma, Inc. (SGP) closed at USD 32.86 on Wednesday, October 28, 2026, up 6.34% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 30.9; the Oct 28, 2026 session ranged USD 30.03–33.47 on volume of 211,716 shares. Market capitalization is $1.10B, with a 52-week range of USD 17.06–33.47 (NMS). Source: Nexqual, retrieved October 29, 2026 at 08:48 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SGP.md
Key facts (SGP)
- Analysts: Buy (mean 1.83 on a 1–5 scale) (6 analysts), mean target USD 44 (range 37–62).
- Total return with dividends: 1Y +24.5% vs S&P 500 +13.6%; 5Y +24.5% vs S&P 500 +79.8%.
- Next earnings: 2026-11-05, EPS estimate USD -0.62, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SGP)
| USD | FY2024 | FY2025 | TTM |
|---|---|---|---|
| Operating income | -$27.1M | -$41.4M | -$54.1M |
| Net income | -$29.2M | -$39.9M | -$51.2M |
| EPS (diluted) | -$16.31 | -$17.98 | — |
| Free cash flow | -$24.0M | -$33.5M | -$45.7M |
| Cash + short-term investments | $16.3M | $96.4M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (SGP)
P/B 4.7x · FCF yield -4.16% · Earnings yield -4.66%
Analysts (SGP)
Consensus Buy (mean 1.83 on a 1–5 scale), 6 analysts; mean target USD 44 (low 37, high 62).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | HC Wainwright & Co. | Reiterated | Buy | $37 |
| 2026-10-05 | HC Wainwright & Co. | Reiterated | Buy | $37 |
| 2026-08-14 | Raymond James | Initiated | Outperform | $39 |
Total return (dividends reinvested) (SGP)
| 1Y (from 2026-02-06) | 5Y (from 2026-02-02) | |
|---|---|---|
| Total return | +24.5% | +24.5% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | — | — |
| Volatility (annualized) | 61.5% | 60.1% |
| Max drawdown | -40.8% (Feb 2026→Jun 2026) | -37.1% (Feb 2026→Jun 2026) |
SGP earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.59 | −$0.55 | Miss −7.3% | — |
| — | Quarter ended Mar 31, 2026 | −$0.69 | −$0.36 | Miss −91.7% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
SGP recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 19, 2026 | 8-K | Other material event “On October 19, 2026, SpyGlass Pharma, Inc. issued a press release providing positive interim 4-year data from its first-in-human trial of its Bimatoprost Drug Pad-IOL System. A copy of this press release is attached hereto as Exhibit 99.1.” |
| Oct 1, 2026 | 8-K | Regulation FD disclosure; Other material event “On October 1, 2026, the Company entered into a Stock Purchase Agreement (the "Purchase Agreement") with Santen Holdings US, Inc., a California corporation ("Seller"), and Santen Pharmaceutical Co., Ltd., a Japanese Company ("Parent"). At the closing under the Purchase Agreement, which occurred on October 1, 2026 (the "Closing"), the Company acquired 100% of the outstanding equity securities (the "Shares") of Advanced Vision Science, Inc., a California corporation ("AVS"), from Seller (the "Acquisition"). Prior to…” |
| Aug 6, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 6, 2026 | 8-K | Quarterly results |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
SGP suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Sands Capital Alternatives | “We are party to an amended and restated investors' rights agreement with certain holders of our capital stock, including entities affiliated with New Enterprise Associates, entities affiliated with RA Capital, entities affiliated with Sands Capital Alternatives, Samsara BioCapital, Vensana Capital I, L.P. and Coöperatieve Gilde Healthcare VG VI U.A.” |
| Partner | Samsara BioCapital | “We are party to an amended and restated investors' rights agreement with certain holders of our capital stock, including entities affiliated with New Enterprise Associates, entities affiliated with RA Capital, entities affiliated with Sands Capital Alternatives, Samsara BioCapital, Vensana Capital I, L.P. and Coöperatieve Gilde Healthcare VG VI U.A.” |
| Partner | Vensana Capital I | “We are party to an amended and restated investors' rights agreement with certain holders of our capital stock, including entities affiliated with New Enterprise Associates, entities affiliated with RA Capital, entities affiliated with Sands Capital Alternatives, Samsara BioCapital, Vensana Capital I, L.P. and Coöperatieve Gilde Healthcare VG VI U.A.” |
| Related party | Eli Lilly (LLY) | “From April 1993 to December 2017, Ms. O'Farrell held various executive management positions at Eli Lilly and Company, a pharmaceutical company, including chief procurement officer, senior vice president, policy and finance, and chief financial officer, Lilly USA.” |
| Competitor | AbbVie (ABBV) | “For example, we compete with alternative glaucoma surgical device and ophthalmic laser companies such as Alcon, Allergan (AbbVie), Bausch & Lomb, Glaukos, and Johnson & Johnson, as well as pharmaceutical competitors such as Alcon, Allergan (AbbVie), Astellas, Genentech (Roche) and Regeneron.” |
| Competitor | Johnson & Johnson (JNJ) | “For example, we compete with alternative glaucoma surgical device and ophthalmic laser companies such as Alcon, Allergan (AbbVie), Bausch & Lomb, Glaukos, and Johnson & Johnson, as well as pharmaceutical competitors such as Alcon, Allergan (AbbVie), Astellas, Genentech (Roche) and Regeneron.” |
Quoted from the company's 10-K filed Mar 26, 2026.
SGP company outlook (results filed Aug 6, 2026)
- “Upcoming Milestones • BIM-DRS: Initiation of the FIH trial expected in the second half of 2026. • BIM-IOL System: Four-year efficacy and safety follow-up expected in fourth quarter of 2026.”
- “These forward-looking statements are made as of the date of this press release, and SpyGlass Pharma assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.”
Quoted word-for-word from the SEC 8-K results press release.
SGP analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.62 | $-0.58 | −$0.04 | $0 | 6 |
| Next quarter (ends Dec 2026) | $-0.65 | $-0.61 | −$0.04 | $0 | 6 |
| Current fiscal year (ends Dec 2026) | $-2.50 | $-2.31 | −$0.19 | $0 | 6 |
| Next fiscal year (ends Dec 2027) | $-2.81 | $-2.70 | −$0.12 | $0 | 6 |
Key Statistics (as of October 29, 2026 at 08:48 UTC)
| Price | USD 32.86 |
|---|---|
| Change | ▲ 6.34% (up) |
| Previous Close | USD 30.9 |
| Open | USD 30.9 |
| Day Range | USD 30.03 – 33.47 |
| 52-Week Range | USD 17.06 – 33.47 |
| Volume | 211,716 shares |
| Market Cap | $1.10B |
| Exchange | NMS |
Technical Analysis (SGP)
Nexqual's technical model rates SGP "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 29, 2026 at 08:48 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 74.64 (overbought) |
| vs SMA50 | Above (USD 27) |
| MACD | 1.12 (positive) |
Analyst Ratings (SGP)
Wall Street analysts rate SGP "Buy" based on 6 analysts, with a mean price target of USD 44 (range USD 37–62), per Nexqual as of October 29, 2026 at 08:48 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 44 |
| High Target | USD 62 |
| Low Target | USD 37 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (SGP)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.62 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.59 vs est -0.55 ▼ miss |
| 2026-03-31 | USD -0.69 vs est -0.36 ▼ miss |
Source: Nexqual, October 29, 2026 at 08:48 UTC.
Financials & Fundamentals (SGP)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.01 |
| Current Ratio | 25.06 |
| Total Cash | $234.19M |
| Total Debt | $1.63M |
Source: Nexqual, October 29, 2026 at 08:48 UTC.
Financial Health Score (SGP)
Nexqual rates SpyGlass Pharma, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 08:48 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $234M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$33M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -22%, ROA -21.0% (last 4 quarters, SEC) |
Ownership (SGP)
| Insider Ownership | +4.28% |
|---|---|
| Institutional Ownership | +94.68% |
| Shares Outstanding | 33.45M |
| Float | 6.50M |
| Short % of Float | +11.03% |
Source: Nexqual, October 29, 2026 at 08:48 UTC.
Leadership (SGP)
SpyGlass Pharma, Inc. is led by Patrick H. Mooney, CEO & Director, per Nexqual as of October 29, 2026 at 08:48 UTC.
| CEO & Director | Patrick H. Mooney |
|---|---|
| Co-Founder, President, Chief Medical Officer & Executive Chairman | Malik Y. Kahook |
| Co-founder & Chief Technology Advisor | Glenn Sussman |
| Chief Financial Officer | Jean-Frederic Viret |
| Chief Operating Officer | James Robert Dennewill |
Major Backers & Investors (SGP)
Notable institutional backers of SpyGlass Pharma, Inc. include RA Capital Management, L.P., NEA Management Company, LLC, Sands Capital Alternatives, LLC, according to Nexqual as of October 29, 2026 at 08:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 23.99% |
| NEA Management Company, LLC | 22.11% |
| Sands Capital Alternatives, LLC | 7.48% |
| Samsara BioCapital, LLC | 6.31% |
| Price (T.Rowe) Associates Inc | 2.02% |
| Vestal Point Capital, LP | 2% |
| JPMorgan | 1.88% |
| Deerfield Management Company, L.P | 1.65% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 2.13% |
Source: Nexqual, October 29, 2026 at 08:48 UTC.
From SpyGlass Pharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Our technology is a novel, proprietary non-bioerodible drug delivery platform (the SpyGlass Platform) that is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye.
- Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).
- We believe this approach positions us to pursue a streamlined regulatory approval process under the FDA's 505(b)(2) pathway because the active ingredient in our BIM-IOL System, bimatoprost, has been previously approved by the FDA.
- We estimate that the total addressable market in the United States for the BIM-IOL System is approximately $13 billion based on the estimated one million glaucoma and OHT patients expected to undergo cataract surgery in 20254, the percentage of patients with glaucoma who have OAG5, and the wholesale acquisition cost for iDose TR.
Legal & Regulatory Risks (Item 1A, quoted)
- The clinical trials of our product candidates may not demonstrate safety and efficacy to the satisfaction of the FDA or other comparable foreign regulatory authorities or otherwise produce positive results.
- We may experience difficulty in patient enrollment in our clinical trials for a number of reasons.
- Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.
- Additional time may be required to obtain regulatory approval for our product candidates because they are combination products.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| ABVX | Abivax SA | USD 89.84 | ▲ 3.26% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 08:48 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt